Cardiometabolic

EVOLV-Rx is an automated data processing system that identifies low-value prescribing practices by extracting and analyzing subject data from multiple sources with varying data formats.

This tool leverages longitudinal data from the Study of Women’s Health Across the Nation (SWAN) to deliver personalized 10-year cardiovascular risk estimates for midlife women.

University of Pittsburgh researchers are developing a mobile and web application to assist clinicians in real-time calculation of the Pittsburgh Cardiac Arrest Category (PCAC) score.

University of Pittsburgh researchers have used the CRISPR technology to create a new mouse model for a rare, recessive metabolic disorder.

Researchers at the University of Pittsburgh have developed fully human monoclonal antibodies (mAbs) targeting the acetylhydrolase PLA2G7, which is secreted by macrophages and interacts with oxidized low-density lipoprotein (oxLDL).

University of Pittsburgh researchers have developed a bio-adaptive hybrid stent that balances high structural support with gradual flexibility, addressing the shortcomings of conventional stents, preventing stent migration, minimizing long-term irritation, and ultimately preventing the need for surgical removal.

NeuroSmart is an AI-driven clinical decision support system (CDSS) designed to optimize stroke management by providing personalized, real-time diagnostic and treatment recommendations.

University of Pittsburgh researchers have developed a novel therapy for chondrocyte aging and, ultimately, osteoarthritis (OA).

Researchers at the University of Pittsburgh and the University of Pennsylvania have identified Profilin1 (Pfn1) as a novel therapeutic target for atherosclerosis.

This is an advanced computational system employing a highly-optimized machine-learning model to provide early and precise prediction of mean blood pressure (MBP) and the associated risk of Post-Induction Hypotension (PIH) in surgical patients.

University of Pittsburgh researchers have developed a novel tool to classify vascular calcification as clinical risk.

University of Pittsburgh and Carnegie Mellon University researchers have developed a novel approach to reducing the risk of intraoperative hypotension (IOH).

Parathyroid hormone (PTH) type 1 receptor (PTHR) is an indispensable G protein-coupled receptor (GPCR) of class B that functions to regulate blood levels of vitamin D, calcium, and phosphate ions in the body, as well as bone turnover.

A University of Pittsburgh researcher has identified a novel treatment strategy for cardiometabolic disease, including heart failure with preserved ejection fraction (HFpEF).

This invention is a novel, in vivo, luciferase-based reporter animal model that provides a dynamic, quantifiable measure of methionine metabolism in living organisms.